Highest-materiality recent filing
VolitionRx prices $4.6M public offering of common stock and warrants
Offered 2,960,000 shares at $1.55 each plus half-warrant; gross proceeds ~$4.6M.
Breached minimum market capitalization covenant on $7.5M (2025) and $2.4M (2026) convertible notes to Lind.
VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test
Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026
Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.
NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review
Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).
VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%
Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments
Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.
Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.
VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants
Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.
VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic
Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.
VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering
Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.
VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe
Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.
VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M
Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.
VolitionRx announces $2.3M registered direct offering; insiders buy 2.36M shares at $0.55
2,363,636 shares sold to insiders (directors, officers, existing stockholders) at $0.55/share.
VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months
Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.
VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023
Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).
Gross proceeds of ~$7M from sale of 12.7M shares/pre-funded warrants at $0.55 each; warrants exercisable at $0.57.
VolitionRx shareholders approve 75% increase in authorized shares to 175M and new equity plan
Authorized shares increased from 100M to 175M (75% increase), effective July 2, 2024 via Certificate of Amendment.
VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024
Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.
VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M
Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.
VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer
Received $13.0 million in milestone payments from Heska Corporation.
VolitionRx secures ~$5.5M financing from Belgian regional government WE
Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.
VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs
Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.
Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.
VolitionRx prices $16.5M public offering of 13M shares at $1.27 per share
Gross proceeds of $16.5M from 13M shares at $1.27/share; net proceeds ~$15.4M.
VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones
Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.
VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront
Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).
On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
On September 30, 2024, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to seven (7) members and appointed Dr. Ethel Rubin to fill the new vacancy on the Board effective as of September 30, 2024.
Dr. Faulkes will also step down as Executive Chairman, and Dr. Futcher will also step down as a member and Chair of the Board’s Nominations and Governance Committee and member of the Audit Committee, at the same time.
Assuming the re-election of the Board-nominated director nominees at the Annual Meeting, the Board has appointed Guy Innes as interim Chairman of the Board and as the Chair of the Nominations and Governance Committee, effective immediately upon such re-election, in addition to his continuing role as a member and Chair of the Audit Committee.
On April 24, 2024, Dr. Martin Faulkes and Dr. Edward Futcher each informed the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of their intention to retire from the Board of the Company following the conclusion of the current director service year and to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which is expected to be held on July 2, 2024.
On November 22, 2022, Dr. Jason Terrell tendered written notice to VolitionRx Limited (the “Company”) of his resignation as Chief Medical Officer of the Company, effective as of November 18, 2022.
On August 15, 2022, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to nine (9) members and appointed Ms. Mickie Henshall to fill the new vacancy on the Board effective as of August 15, 2022.
Max materiality 0.80 · Median 0.60 · Most common event other_material